<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818610</url>
  </required_header>
  <id_info>
    <org_study_id>3200B0-120074/1</org_study_id>
    <nct_id>NCT00818610</nct_id>
  </id_info>
  <brief_title>Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia</brief_title>
  <acronym>BICAP</acronym>
  <official_title>Beta-lactam Monotherapy Versus Beta-lactam - Macrolide Association as Empiric Antibiotherapy Strategies in Non-severe Hospitalized Community-acquired Pneumonia: a Randomized, Non-inferiority, Open Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss National Fund for Scientific Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss National Fund for Scientific Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not
      inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with
      community-acquired pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Clinical Stability (hours)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>in-hospital, at 30 and at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">601</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bi-therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta lactam (amoxicillin / clav. acid OR cefuroxime)</intervention_name>
    <description>1.2 g 4x/d OR 1.5 g 3x/d IV</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Augmentin</other_name>
    <other_name>Zinacef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)</intervention_name>
    <description>1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO</description>
    <arm_group_label>Bi-therapy</arm_group_label>
    <other_name>Augmentin</other_name>
    <other_name>Zinacef</other_name>
    <other_name>Klacid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years

          -  New infiltrate on chest X-ray, unexplained by another disease process

          -  Presence of at least two of the following findings suggestive of pneumonia: fever or
             hypothermia, new or increasing cough, sputum production, pleuritic chest pain,
             tachypnea, dyspnea or focal signs on chest examination

          -  Need for hospitalization as defined by the emergency physician in charge of the
             patient

        Exclusion Criteria:

          -  Allergy to one of the study drugs

          -  Pregnancy

          -  Severe immunosuppression

          -  Recent (&lt;14 d) hospitalization, or currently hospitalized since &gt; 48 hours

          -  Residency in a nursing home

          -  Previous use of more than 24 hours of any antibiotic

          -  Severe community-acquired pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Perrier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Geneva and University Hospital of Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier du Centre du Valais</name>
      <address>
        <city>Sion</city>
        <state>Valais</state>
        <zip>1950</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR-Fribourg, Hôpital Cantonal</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neuchâtelois - La Chaux-de-Fonds</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <zip>2300</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss National Fund for Scientific Research</investigator_affiliation>
    <investigator_full_name>Garin Nicolas</investigator_full_name>
    <investigator_title>Associate physician</investigator_title>
  </responsible_party>
  <keyword>Community-acquired infections</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Clinical Stability</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Combination therapy</keyword>
  <keyword>Atypical bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

